Skip to main content
Premium Trial:

Request an Annual Quote

Humana to Cover NanoString Technologies Prosigna Breast Cancer Test

NEW YORK (GenomeWeb) – NanoString Technologies announced today that health insurer Humana has issued a positive coverage decision for its Prosigna Breast Cancer Gene Signature Assay.

The decision provides Humana's more than 13 million members with access to the test.

"This positive coverage decision is in line with updated ASCO guidelines released in February of 2016, wherein Prosigna is considered medically necessary to assess the necessity of adjuvant chemotherapy in ER-positive, HER2-negative, node-negative breast cancer patients, when adjuvant chemotherapy is not precluded due to any other factor," the company said in a statement.

NanoString CEO Brad Gray added that Humana's decision was an "important milestone in making our Prosigna test available to all indicated patients."

Prosigna provides a numerical score to assess the risk of disease recurrence, based on the PAM50 gene signature and clinical variables. It runs on NanoString's nCounter Dx platform using RNA extracted from formalin-fixed paraffin embedded samples.

Humana is the latest insurer to cover Prosigna — Cigna and Aetna both announced their decisions to cover the test in May 2016.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.